Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 7c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $32.57 million.

2016 Financial Guidance

Vanda reiterates its prior 2016 financial guidance and expects to achieve the following financial objectives in 2016:

• Combined net product sales from both HETLIOZ® and Fanapt® of between $143 and $153 million.
• HETLIOZ® net product sales of between $73 and $78 million and Fanapt® net product sales of between $70 and $75 million.
• Non-GAAP Operating expenses, excluding Cost of goods sold, of between $125 and $135 million.
• Non-GAAP Operating expenses excludes intangible asset amortization expense of $10.9 million and stock-based compensation of between $9 and $11 million.
• Year end 2016 Cash is expected to be between $123 and $143 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Vanda Pharmaceuticals (VNDA) PT Lowered to $20 at H.C. Wainwright
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c